Author | Julia von Tresckow, MD | OncLive

Author | Julia von Tresckow, MD


Dr. von Tresckow on "Sequential Triple-T" Trial in CLL

January 14, 2017


Julia von Tresckow, MD, specialist in oncology, University of Cologne, Department of Internal Medicine, and Center of Integrated Oncology Cologne-Bonn, German CLL Study Group, discusses the CLL2-BIG trial, which explored the combination of obinutuzumab (Gazyva) and ibrutinib (Imbruvica) for induction and maintenance treatment of physically fit and unfit patients with chronic lymphocytic leukemia (CLL). Patients with high tumor burden were given bendamustine as debulking.